

RECORDATI: PUBLICATION OF LISTS OF CANDIDATES FOR THE APPOINTMENT OF DIRECTOR AND STATUTORY AUDITOR OF THE COMPANY

Milan, 20 March 2017 – Pursuant to art. 144-octies, paragraph 1 of Consob's Regulation 11971/1999 ("Issuers' Regulations") and with reference to the Shareholders Ordinary and Extraordinary General Meeting to be held on 11th April 2017 in a single call, RECORDATI S.p.A. informs that the following documents are available to the public at the Company's registered offices, on the "1info" storage mechanism (www.1info.it) and on the Company's website (www.recordati.it section Investors/Shareholders Meetings):

- the lists for the appointment of the Directors and of the Statutory Auditors filed by the majority shareholder, Fimei S.p.A., which owns 51,79% of RECORDATI S.p.A.'s share capital;
- the list for the appointment of the Statutory Auditors, filed by a group of institutional investors which collectively own about 0.7591% of RECORDATI S.p.A.'s share capital.

Please note that the above mentioned lists are available jointly with the relevant documentation requested by law and by the Company's By-laws.

Recordati, established in 1926, is an international pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271), with a total staff of more than 4,100, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. Headquartered in Milan, Italy, Recordati has operations in the main European countries, in Russia, in other Central and Eastern European countries, in Turkey, in North Africa, in the United States of America, in Mexico and in some South American countries. An efficient field force of medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in a number of therapeutic areas including a specialized business dedicated to treatments for rare diseases. Recordati is a partner of choice for new product licenses for its territories. Recordati is committed to the research and development of new specialties within the urogenital therapeutic area and of treatments for rare diseases. Consolidated revenue for 2016 was € 1,153.9 million, operating income was € 327.4 million and net income was € 237.4 million.

For further information:

Recordati website: www.recordati.com

Investor Relations

Marianne Tatschke
(39)0248787393
e-mail: inver@recordati.it

Media Relations

Studio Noris Morano
(39)0276004736, (39)0276004745
e-mail: norismorano@studionorismorano.com

RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.A.

Sede Legale
VIA M. CIVITALI, 1
20148 MILANO, ITALIA
TEL. (39) 0248787.1
FAX (39) 0240073747

CAPITALE SOCIALE € 26.140.644,50 I.V.
REG. IMP. MILANO N. 00748210150
CODICE FISCALE/P.IVA 007482210150
R.E.A. MILANO N. 401832